Endocrine Pathology

Official Twitter Page of the Endocrine Pathology Society and its companion journal, Endocrine Pathology #EndoPath #USCAP #EndoPathSociety #EndocrinePathology

[Endocrine Pathology @EndoPath]

Interesting #EndoPath data? Send us your article! Fast turn around & expert reviewers! Make our journal your voice! https://t.co/4QtKLi5zBo

[Endocrine Pathology @EndoPath]

Can we predict metastatic risk in papillary thyroid carcinoma at diagnosis?

A new study validates THYT1, a ddPCR-based genetic signature identifying up to 80% of metastatic cases - even years before metastasis.

https://t.co/R7oPt6Udhw

[Endocrine Pathology @EndoPath]

Thymic and pulmonary neuroendocrine neoplasms look alike - but are they molecularly similar?

New multi-omics research reveals distinct NET profiles, overlapping NEC signatures, and CD44 as a promising marker of pulmonary origin!

https://t.co/wVKlCXFnoJ

[Endocrine Pathology @EndoPath]

🚨 c-MYC may help distinguish neuroendocrine carcinomas (NEC) from tumors (NET). In 1,380 neuroendocrine neoplasms, c-MYC was expressed in 43% of NEC vs 2% of NET/carcinoids. Strong positivity may support NEC classification in borderline cases!

https://t.co/NZ2yMMRuMO

[Endocrine Pathology @EndoPath]

🔬 Ampullary somatostatin-producing (D-cell) neuroendocrine tumors are rare and poorly characterized. A multicenter study reveals distinctive diagnostic features and potentially actionable kinase-related alterations in 64% of tumors!

https://t.co/qXkVaBHHcS

[Endocrine Pathology @EndoPath]

ECP2026 in Stockholm with endocrine pathologists Christofer Juhlin, Sylvia Asa and Ozgur Mete 🇸🇪🔬

[Endocrine Pathology @EndoPath]

ECP2026 in Stockholm with endocrine pathologists Christofer Juhlin, Sylvia Asa and Ozgur Mete 🇸🇪🔬

[Endocrine Pathology @EndoPath]

Endocrine pathology came out in full force at ECP2026 in Stockholm, Sweden!

Depicted here are three leaders in the field who need no formal introduction: Silvia Uccella, Ozgur Mete and Sylvia Asa!

[Endocrine Pathology @EndoPath]

🇸🇪 Endocrine Pathology at #ECP2026 in Stockholm!

Monday highlights: 🧩 The Endocrine Challenge, 🏆 Best Poster Session & 🧬 Adrenal and paraganglia: are there new kids on the blocks?

From morphology to molecular diagnostics - lots to discuss!

https://t.co/Nf9CgZBY2i

[Endocrine Pathology @EndoPath]

🇸🇪 Endocrine Pathology at #ECP2026 in Stockholm!

Monday highlights: 🧩 The Endocrine Challenge, 🏆 Best Poster Session & 🧬 Adrenal and paraganglia: are there new kids on the blocks?

From morphology to molecular diagnostics - lots to discuss!

https://t.co/Nf9CgZBY2i

[Endocrine Pathology @EndoPath]

Can we better predict recurrence in non-functioning pancreatic NET? 🧬

No recurrences occurred in tumors with isolated Menin loss, vs 48% with ATRX/DAXX loss - highlighting the potential of molecular risk stratification to guide follow-up.

Read it here:

https://t.co/LFaz6MEKha

[Endocrine Pathology @EndoPath]

Rare. Aggressive. Biologically complex. 🧬

Bladder neuroendocrine neoplasms challenge current classifications. This review uncovers their molecular heterogeneity and proposes a bladder-specific framework to sharpen diagnosis and personalized medicine.

https://t.co/XBrQNOsLdt

[Endocrine Pathology @EndoPath]

🧬 New PPGL genetics research:

Germline testing found pathogenic variants in nearly one-third of 110 pheo/paraganglioma patients, highlighting the value of tiered testing and equitable variant interpretation across diverse populations.

https://t.co/9erfo77cOU

[Endocrine Pathology @EndoPath]

🔬 New in Endocrine Pathology: Necrosis in paragangliomas (only 3.9% of cases) is linked to 75% metastasis rate (vs 10%), larger tumors & cardiovascular complications. Cystic changes don't affect outcomes. Pathology matters for risk stratification!

https://t.co/WdXVZULBez

[Endocrine Pathology @EndoPath]

💡 A new genetic cause of hereditary hyperparathyroidism?

New findings implicate fumarate hydratase (FH) deficiency in a subset of parathyroid adenomas - expanding the phenotypic spectrum of FH tumor predisposition syndromes!

https://t.co/DCrHswe2Ny

[Endocrine Pathology @EndoPath]

🩸 Could ctDNA improve monitoring of adrenocortical carcinoma?

In 87 tests from 20 patients, ctDNA showed 88% sensitivity, 91.7% specificity - and strongly correlated with tumor burden (R=0.844).

Promising evidence for personalized ACC surveillance!

https://t.co/QcnD0hQ7Tx

[Endocrine Pathology @EndoPath]

Where do rare renal neuroendocrine tumors come from? 🕵🏼‍♀️

Genomic & transcriptomic profiling of RenNETs reveals neuroendocrine programs, universal SSTR2A expression and genetic evidence that GI-type epithelium may be a precursor in some cases.

https://t.co/uhu5TepA5i

[Endocrine Pathology @EndoPath]

🦋 Multifocal fibrosing thyroiditis: rarer - or simply underrecognized?

Found in 1.56% of 1,736 thyroid resections, MFT can mimic papillary thyroid carcinoma and frequently coexists with other thyroid lesions.

A closer look at this enigmatic entity 👇

https://t.co/T4Hu4BSgOo

[Endocrine Pathology @EndoPath]

🧬 Could RNA splicing help explain PanNET heterogeneity?

Analysis of 174 tumors reveals 3 distinct “spliceosomic” groups with unique clinical, molecular & splicing profiles - opening new avenues for biomarkers and personalized therapy.

https://t.co/kXpweesEXl

[Endocrine Pathology @EndoPath]

🧬 Are all ALK rearrangements in oncocytic thyroid tumors equal? Not necessarily.

New research shows STRN::ALK transcript heterogeneity, only canonical in-frame fusions showed ALK protein expression.

Resd why FISH-positive ≠ ALK-driven 👇

https://t.co/R5YdAZeffo

[Endocrine Pathology @EndoPath]

Are gallbladder neuroendocrine tumors really aggressive?

A new study in Endocrine Pathology suggests most GB-NETs are small, low-grade, and indolent, with tumor size and grade emerging as key predictors of metastatic risk.

https://t.co/6NKPAZvMX6